MedPath

Fulgent Pharma LLC

Fulgent Pharma LLC logo
🇺🇸United States
Ownership
Subsidiary
Established
2011-06-01
Employees
-
Market Cap
-
Website
http://www.fulgentpharma.com

Clinical Trials

2

Active:0
Completed:0

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

Study of FID-022 in Participants with Advanced Solid Tumors

Phase 1
Not yet recruiting
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2024-11-19
Last Posted Date
2024-11-19
Lead Sponsor
Fulgent Pharma LLC.
Target Recruit Count
24
Registration Number
NCT06694480

FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma

Phase 2
Recruiting
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
First Posted Date
2024-03-27
Last Posted Date
2024-11-07
Lead Sponsor
Fulgent Pharma LLC.
Target Recruit Count
46
Registration Number
NCT06332092
Locations
🇺🇸

Highlands Oncology - North Hills, Fayetteville, Arkansas, United States

🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

🇺🇸

Moffitt Cancer Center Magnolia Campus, Tampa, Florida, United States

and more 3 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.